Jay H Hoofnagle1, Herbert L Bonkovsky2,3, Elizabeth J Phillips4, Yi-Ju Li5, Jawad Ahmad6, Huiman Barnhart5, Francisco Durazo7, Robert J Fontana8, Jiezhun Gu5, Ikhlas Khan9, David E Kleiner10, Christopher Koh11, Don C Rockey12, Leonard B Seeff13, Jose Serrano1, Andrew Stolz14, Hans L Tillmann15, Raj Vuppalanchi16, Victor J Navarro13. 1. Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD. 2. National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD. 3. Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC. 4. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. 5. Duke Clinical Research Institute, Duke University, Durham, NC. 6. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. 7. University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA. 8. Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI. 9. National Center for Natural Products Research, University of Mississippi, University, MI. 10. The Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD. 11. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD. 12. Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC. 13. Department of Medicine, Einstein Healthcare Network, Philadelphia, PA. 14. Department of Medicine, University of Southern California School of Medicine, Los Angeles, CA. 15. Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, East Carolina University, Greenville, NC. 16. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Abstract
BACKGROUND AND AIMS: Herbal supplements, and particularly multi-ingredient products, have become increasingly common causes of acute liver injury. Green tea is a frequent component in implicated products, but its role in liver injury is controversial. The aim of this study was to better characterize the clinical features, outcomes, and pathogenesis of green tea-associated liver injury. APPROACH AND RESULTS: Among 1,414 patients enrolled in the U.S. Drug-Induced Liver Injury Network who underwent formal causality assessment, 40 cases (3%) were attributed to green tea, 202 to dietary supplements without green tea, and 1,142 to conventional drugs. The clinical features of green tea cases and representation of human leukocyte antigen (HLA) class I and II alleles in cases and control were analyzed in detail. Patients with green tea-associated liver injury ranged in age from 17 to 69 years (median = 40) and developed symptoms 15-448 days (median = 72) after starting the implicated agent. The liver injury was typically hepatocellular (95%) with marked serum aminotransferase elevations and only modest increases in alkaline phosphatase. Most patients were jaundiced (83%) and symptomatic (88%). The course was judged as severe in 14 patients (35%), necessitating liver transplantation in 3 (8%), but rarely resulting in chronic injury (3%). In three instances, injury recurred upon re-exposure to green tea with similar clinical features, but shorter time to onset. HLA typing revealed a high prevalence of HLA-B*35:01, found in 72% (95% confidence interval [CI], 58-87) of green tea cases, but only 15% (95% CI, 10-20) caused by other supplements and 12% (95% CI, 10-14) attributed to drugs, the latter rate being similar to population controls (11%; 95% CI, 10.5-11.5). CONCLUSIONS: Green tea-related liver injury has distinctive clinical features and close association with HLA-B*35:01, suggesting that it is idiosyncratic and immune mediated.
BACKGROUND AND AIMS: Herbal supplements, and particularly multi-ingredient products, have become increasingly common causes of acute liver injury. Green tea is a frequent component in implicated products, but its role in liver injury is controversial. The aim of this study was to better characterize the clinical features, outcomes, and pathogenesis of green tea-associated liver injury. APPROACH AND RESULTS: Among 1,414 patients enrolled in the U.S. Drug-Induced Liver Injury Network who underwent formal causality assessment, 40 cases (3%) were attributed to green tea, 202 to dietary supplements without green tea, and 1,142 to conventional drugs. The clinical features of green tea cases and representation of human leukocyte antigen (HLA) class I and II alleles in cases and control were analyzed in detail. Patients with green tea-associated liver injury ranged in age from 17 to 69 years (median = 40) and developed symptoms 15-448 days (median = 72) after starting the implicated agent. The liver injury was typically hepatocellular (95%) with marked serum aminotransferase elevations and only modest increases in alkaline phosphatase. Most patients were jaundiced (83%) and symptomatic (88%). The course was judged as severe in 14 patients (35%), necessitating liver transplantation in 3 (8%), but rarely resulting in chronic injury (3%). In three instances, injury recurred upon re-exposure to green tea with similar clinical features, but shorter time to onset. HLA typing revealed a high prevalence of HLA-B*35:01, found in 72% (95% confidence interval [CI], 58-87) of green tea cases, but only 15% (95% CI, 10-20) caused by other supplements and 12% (95% CI, 10-14) attributed to drugs, the latter rate being similar to population controls (11%; 95% CI, 10.5-11.5). CONCLUSIONS: Green tea-related liver injury has distinctive clinical features and close association with HLA-B*35:01, suggesting that it is idiosyncratic and immune mediated.
Authors: Maricruz Vega; Manisha Verma; David Beswick; Stephanie Bey; Jared Hossack; Nathan Merriman; Ashish Shah; Victor Navarro Journal: Drug Saf Date: 2017-09 Impact factor: 5.606
Authors: Susanne M Henning; Claudia Fajardo-Lira; Hyun W Lee; Arthur A Youssefian; Vay L W Go; David Heber Journal: Nutr Cancer Date: 2003 Impact factor: 2.900
Authors: Elizabeth X Zheng; Simona Rossi; Robert J Fontana; Raj Vuppalanchi; Jay H Hoofnagle; Ikhlas Khan; Victor J Navarro Journal: Drug Saf Date: 2016-08 Impact factor: 5.606
Authors: Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: Paola Nicoletti; Guruprasad P Aithal; Einar S Bjornsson; Raul J Andrade; Ashley Sawle; Marco Arrese; Huiman X Barnhart; Emmanuelle Bondon-Guitton; Paul H Hayashi; Fernando Bessone; Alfonso Carvajal; Ingolf Cascorbi; Elizabeth T Cirulli; Naga Chalasani; Anita Conforti; Sally A Coulthard; Mark J Daly; Christopher P Day; John F Dillon; Robert J Fontana; Jane I Grove; Pär Hallberg; Nelia Hernández; Luisa Ibáñez; Gerd A Kullak-Ublick; Tarja Laitinen; Dominique Larrey; M Isabel Lucena; Anke H Maitland-van der Zee; Jennifer H Martin; Mariam Molokhia; Munir Pirmohamed; Elizabeth E Powell; Shengying Qin; Jose Serrano; Camilla Stephens; Andrew Stolz; Mia Wadelius; Paul B Watkins; Aris Floratos; Yufeng Shen; Matthew R Nelson; Thomas J Urban; Ann K Daly Journal: Gastroenterology Date: 2016-12-30 Impact factor: 22.682
Authors: Raj Vuppalanchi; Herbert L Bonkovsky; Jawad Ahmad; Huiman Barnhart; Francisco Durazo; Robert J Fontana; Jiezhun Gu; Ikhlas Khan; David E Kleiner; Christopher Koh; Don C Rockey; Elizabeth J Phillips; Yi-Ju Li; Jose Serrano; Andrew Stolz; Hans L Tillmann; Leonard B Seeff; Jay H Hoofnagle; Victor J Navarro Journal: Clin Gastroenterol Hepatol Date: 2021-08-14 Impact factor: 13.576